

FACT SHEET As of 12/31/23

PHARMACEUTICALS ULTRASECTOR PROFUND

Fund objective

Pharmaceuticals UltraSector ProFund seeks daily investment results, before fees and expenses, that correspond to one and one-half times (1.5x) the daily performance of the S&P Pharmaceuticals Select Industry Index. The Fund does not seek to achieve its stated investment objective over a period of time greater than a single day.

Fund details

Inception Date	06/28/2000
Investor Class Symbol	PHPIX
Service Class Symbol	PHPSX
Investor Class Cusip	743185423
Service Class Cusip	743185415
Investor Class Gross Expense Ratio	2.27%
Service Class Gross Expense Ratio	3.27%
Investor Class Net Expense Ratio ¹	1.78%
Service Class Net Expense Ratio ¹	2.78%
Limit on Exchange	None

Uses for magnified exposure

Common uses for magnified exposure include:

- Seeking magnified gains (will also magnify losses)
- Getting a target level of exposure for less cash
- Overweighting a market segment without additional cash

Fund performance and index history²


The Pharmaceuticals UltraSector ProFund seeks daily investment results, before fees and expenses, that are 1.5x the return of the S&P Pharmaceuticals Select Industry Index (the "Index") for a single day, not for any other period.

	4Q 2023	Year to Date	1-Year	5-Year	10-Year	Fund Inception
Investor Class NAV Total Return	5.90%	-11.27%	-11.27%	5.13%	4.93%	2.17%
Service Class NAV Total Return	5.64%	-12.10%	-12.10%	4.09%	3.88%	1.18%
S&P Pharmaceuticals Select Industry	4.97%	2.77%	2.77%	3.57%	1.43%	6.30%
Dow Jones U.S. Select Pharmaceuticals	5.01%	1.25%	1.25%	7.68%	6.42%	—

Periods greater than one year are annualized.

On 8/28/18 the benchmark for this fund changed from tracking the Dow Jones U.S. Sector indexes to Dow Jones U.S. Select Sector Indexes (inception 4/28/06)

Daily return during 4Q 2023




Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than the original cost. Performance data current to the most recent month-end is available at Profunds.com or by calling 1-888-776-3637.

For standardized returns year-to-date, and as of the most recent calendar quarter-end, and annualized month-end, see performance. Returns include the reinvestment of dividends and capital gains.

¹Contractual waiver effective until November 30, 2024. Without such a waiver of fees, the total returns would have been lower.

²All data, unless otherwise noted, is as of 12/31/23, and for Investor Class Shares only. Holdings and other data are subject to change.

<h2>Index description ²</h2> <p>The Index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI"). The S&P TMI is designed to track the broad U.S. equity market. The pharmaceuticals segment of the S&P TMI comprises the following Global Industry Classification Standard (GICS®) sub-industry: pharmaceuticals.</p>	<h2>Top index companies ²</h2> <table> <thead> <tr> <th></th><th>Weights</th></tr> </thead> <tbody> <tr><td>Organon & Co.</td><td>5.36%</td></tr> <tr><td>Catalent Inc.</td><td>4.95%</td></tr> <tr><td>Intra-Cellular Therapies Inc.</td><td>4.86%</td></tr> <tr><td>Elanco Animal Health Inc.</td><td>4.77%</td></tr> <tr><td>Axsome Therapeutics Inc.</td><td>4.64%</td></tr> <tr><td>Viatris Inc.</td><td>4.51%</td></tr> <tr><td>Perrigo Co. plc</td><td>4.44%</td></tr> <tr><td>Zoetis Inc.</td><td>4.38%</td></tr> <tr><td>CymaBay Therapeutics Inc.</td><td>4.35%</td></tr> <tr><td>Merck & Co. Inc.</td><td>4.30%</td></tr> </tbody> </table>		Weights	Organon & Co.	5.36%	Catalent Inc.	4.95%	Intra-Cellular Therapies Inc.	4.86%	Elanco Animal Health Inc.	4.77%	Axsome Therapeutics Inc.	4.64%	Viatris Inc.	4.51%	Perrigo Co. plc	4.44%	Zoetis Inc.	4.38%	CymaBay Therapeutics Inc.	4.35%	Merck & Co. Inc.	4.30%
	Weights																						
Organon & Co.	5.36%																						
Catalent Inc.	4.95%																						
Intra-Cellular Therapies Inc.	4.86%																						
Elanco Animal Health Inc.	4.77%																						
Axsome Therapeutics Inc.	4.64%																						
Viatris Inc.	4.51%																						
Perrigo Co. plc	4.44%																						
Zoetis Inc.	4.38%																						
CymaBay Therapeutics Inc.	4.35%																						
Merck & Co. Inc.	4.30%																						
<h2>Index Characteristics ²</h2> <table> <tbody> <tr><td>Number of Companies</td><td>36</td></tr> <tr><td>Price/Earnings Ratio</td><td>36.52</td></tr> <tr><td>Price/Book Ratio</td><td>2.65</td></tr> <tr><td>Dividend Yield</td><td>1.61%</td></tr> <tr><td>Average Market Cap</td><td>\$46.17 billion</td></tr> </tbody> </table>	Number of Companies	36	Price/Earnings Ratio	36.52	Price/Book Ratio	2.65	Dividend Yield	1.61%	Average Market Cap	\$46.17 billion	<h2>Index sectors ²</h2> <table> <thead> <tr> <th></th><th>Weights³</th></tr> </thead> <tbody> <tr> <td>■ Pharmaceuticals</td><td>100.00%</td></tr> </tbody> </table> 		Weights ³	■ Pharmaceuticals	100.00%								
Number of Companies	36																						
Price/Earnings Ratio	36.52																						
Price/Book Ratio	2.65																						
Dividend Yield	1.61%																						
Average Market Cap	\$46.17 billion																						
	Weights ³																						
■ Pharmaceuticals	100.00%																						
<p>For more information, visit ProFunds.com or ask your financial advisor or broker.</p>																							

Narrowly focused investments typically exhibit higher volatility.

Many ProFunds routinely employ leveraged investment techniques that magnify gains and losses, and result in greater volatility in value. Each geared (leveraged or inverse) ProFund seeks a return that is a multiple (e.g., 2x, -1x) of the return of an index or other benchmark (target) **for a single day**. Due to the compounding of daily returns, geared ProFunds' returns over periods other than one day will likely differ in amount and possibly direction from the target return for the same period. These effects may be more pronounced in funds with larger or inverse multiples and in funds with volatile benchmarks. Investors should monitor their ProFunds holdings consistent with their strategies, as frequently as daily. For more on risks, please read the prospectus.

ProFunds are not suitable for all investors because of the sophisticated techniques the funds employ. Investing involves risk, including the possible loss of principal. ProFunds entail certain risks, including risk associated with the use of derivatives (swap agreements, futures contracts and similar instruments), imperfect benchmark correlation, leverage and market price variance, all of which can increase volatility and decrease performance. For more on correlation, leverage and other risks, please read the prospectus. There is no guarantee any ProFund will achieve its investment objective.

All ProFunds are subject to active investor risk. There are no restrictions on the size and frequency of trades and no transaction fees. The frequent exchanges our policies permit can decrease performance, increase expenses and cause investors to incur tax consequences.

Carefully consider the investment objectives, risks, charges and expenses of ProFunds before investing. A prospectus or summary prospectus with this and other information may be obtained at [Profunds.com](https://www.profunds.com) or by calling 1-888-776-3637. Read them carefully before investing.

³Sum of weightings may not equal 100% due to rounding.

ProFunds are distributed by ProFunds Distributors Inc.© 2023